Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$444.8m

Esperion Therapeutics Past Earnings Performance

Past criteria checks 0/6

Esperion Therapeutics's earnings have been declining at an average annual rate of -15.4%, while the Pharmaceuticals industry saw earnings growing at 6.5% annually. Revenues have been declining at an average rate of 2.8% per year.

Key information

-15.4%

Earnings growth rate

3.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-2.8%
Return on equityn/a
Net Margin-202.5%
Next Earnings Update27 Feb 2024

Recent past performance updates

Recent updates

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

Esperion Therapeutics: Deeply Undervalued With An Extremely High Short Interest

Jan 30

Esperion Therapeutics (ESPR) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Bullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Jan 14
Bullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Esperion announces deal with Serometrix and gives out Q4 U.S. products revenue forecast

Jan 13

Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares

Dec 26
Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares

Revenue & Expenses Breakdown
Beta

How Esperion Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:ESPR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 23103-2081210
30 Jun 2388-2221130
31 Mar 2381-2391090
31 Dec 2275-2341090
30 Sep 2272-2431230
30 Jun 2267-2581240
31 Mar 2289-2351540
31 Dec 2178-2691720
30 Sep 2173-3081950
30 Jun 2162-3252180
31 Mar 21234-1562060
31 Dec 20228-1442000
30 Sep 20219-1011600
30 Jun 20216-841290
31 Mar 205-263950
31 Dec 19148-97660
30 Sep 19147-95550
30 Jun 19146-77460
31 Mar 19145-68390
31 Dec 180-202330
30 Sep 180-18027-114
30 Jun 180-17524-74
31 Mar 180-17322-36
31 Dec 170-167210
30 Sep 170-15821139
30 Jun 170-13019112
31 Mar 170-1011884
31 Dec 160-75180
30 Sep 160-591941
30 Jun 160-552135
31 Mar 160-532132
31 Dec 150-502030
30 Sep 150-461828
30 Jun 150-431528
31 Mar 150-401227
31 Dec 140-361125
30 Sep 140-371026
30 Jun 140-321023
31 Mar 140-30819
31 Dec 130-26716
30 Sep 130-19510
30 Jun 130-1739

Quality Earnings: ESPR is currently unprofitable.

Growing Profit Margin: ESPR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ESPR is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare ESPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ESPR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-3.2%).


Return on Equity

High ROE: ESPR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.